Hormone replacement therapy and cardioprotection: Basic concepts and clinical considerations

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 71, Issue 2, 1997, Pages 193-197

  Pines, Amos ^a   Mijatovic, Velja ^b,c   Van Der Mooren, Marius J ^b,c   Kenemans, Peter ^b,c  

^a Ichilov Medical Center   (Israel)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

cardiovascular disease; estrogen; hormone replacement therapy; progestin

Indexed keywords

ESTROGEN; GESTAGEN;

ADULT; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; DRUG EFFECT; ESTROGEN DEFICIENCY; FEMALE; HIGH RISK POPULATION; HORMONE SUBSTITUTION; HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL;

EID: 0031081198     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-2115(96)02634-6     Document Type: Conference Paper

References (42)

1. [1] Wenger NK, Speroff L, Packard B. Cardiovascular health and disease in women. N Engl J Med 1993; 329: 247-256.
2. [2] Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA 1991; 265: 1861-1867.
3. [3] Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease:a quantitative assessment of the epidemiological evidence. Prev Med 1991; 20: 47-63.
4. [4] Grady D, Rubin SM, Petiti DB et al. Hormone replacement to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016-1037.
5. [5] Grodstein F, Stampfer MJ, Manson JE et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335: 453-461.
6. [6] Falkeborn M, Persson I, Adami HO et al. The risk of acute myocardial infarction after oestrogen and oestrogen - progestogen replacement. Br J Obstet Gynaecol 1992; 99: 821-828.
7. [7] Psaty BM, Heckbert SR, Atkins D et al. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med 1994; 154: 1333-1339.
8. [8] Falkeborn M, Persson I, Terent A et al. Hormone replacement therapy and the risk of stroke. Arch Intern Med 1993; 153: 1201-1209.
9. [9] Ettinger B, Friedman GD, Bush T, Quesenberry CP Jr. Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol 1996; 87 (1): 6-12.
10. [10] Mijatovic V, Pines A. Menopause-induced changes in cardiovascular functions and HRT. Eur Menopause J 1995; 2: 4-9.
11. [11] Wouters MGAJ, Moorrees MTEC, Van der Mooren MJ et al.. Plasma homocysteine and menopausal status. Eur J Clin Invest 1995; 25: 801-805.
12. [12] Nabulsi AA, Folsom AR, White A et al. Associations of HRT with various cardiovascular risk factors in postmenopausal women. New Engl J Med 1993; 328: 1069-1075.
13. [13] The writing group for the PEPI-trial. Effects of estrogen or estrogen/progestogen regimens on heart disease risk factors in postmenopausal women. JAMA 1995; 273: 199-208.
14. [14] The writing group for the estradiol clotting factors study. Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: a 1-year, double-blind, placebo-controlled study. Thromb Haemost 1996; 75 (3): 476-480.
15. [15] Ueland PM, Refsum H, Brattstrom L. Plasma homocysteine and cradiovascular disease. In: Francis RB (ed.) Atherosclerotic cradiovascular disease, hemostasis and endothelial function. New York: Marcel Dekker, 1992, pp. 183-236.
16. [16] Van der Mooren MJ, Wouters MGAJ, Blom HJ, Schellekens LA, Eskes TKAB, Rolland R. Hormone replacement therapy may reduce high serum homocysteine in postmenopausal women. Eur J Clin Invest 1994; 24: 733-736.
17. [17] Van der Mooren MJ, Wouters MGAJ, Blom HJ, Schellekens LA, Eskes TKAB, Rolland R. Homocysteine concentrations may decrease during postmenopausal hormone replacement therapy. Ir J Med Sci 1995; 164 (Suppl. 15): 21.
18. [18] Anker G, Lonning PE, Ueland PM, Refsum H, Lien EA. Plasma levels of the atherogenic amino acid homocysteine in postmenopausal women with breast cancer treated with tamoxifen. Int J Cancer 1995; 60: 365-368.
19. [19] Blom HJ, Van der Mooren MJ. Hyperhomocysteinemia: a risk factor for cardiovascular disease - Influence of sex hormones on homocysteine metabolism. Gynecol Endocrinol 1996; 10 (2): 75-79.
20. [20] Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA 1991; 265: 1861-1867.
21. [21] McGill HC. Sex steroid hormone receptors in the cardiovascular system. Postgrad Med 1989; 85: 648-653.
22. [22] Losordo DW, Kearney M, Kim EA, Jekanowski J, Isner JM. Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation 1994; 89: 1501-1510.
23. [23] Karas RH, Patterson BL, Mendelsohn ME. Human vascular smooth muscle cells contain functional estrogen receptors. Circulation 1994; 89: 1943-1950.
24. [24] Polderman KH, Stehouwer CDA, van Kamp GJ, Dekker GA, Verheugt FWA, Gooren LJG. Influence of sex hormones on plasma endothelin levels. Ann Intern Med 1993; 118: 429-432.
25. [25] White MM, Zamudio S, Stevens T, Tyler R, Lindenfeld J, Leslie K, Moore LG. Estrogen, progesterone, and vascular reactivity: potential cellular mechanisms. Endocrine Rev 1995; 6: 739-751.
26. [26] Collins P, Rosano GMC, Jiang C et al. Cardiovascular protection by estrogen; a calcium antagonistic effect? Lancet 1993; 341: 1264-1265.
27. [27] Fischer GM, Cherian K, Swain ML. Increased synthesis of aortic collagen and elastin in experimental atherosclerosis. Inhibition by contraceptive steroids. Atherosclerosis 1981; 39 (4): 463-467.
28. [28] Fischer GM, Swain ML. Effects of estradiol and progesterone on the increased synthesis of collagen in atherosclerotic rabbit aortas. Atherosclerosis 1985; 54 (2): 177-185.
29. [29] Sugioka JM, Shimosegawa Y, Nakano MM. Estrogens as natural antioxidants of membrane lipid peroxidation. FEBS Lett 1987; 210: 37-39.
30. [30] Sack MN, Rader DJ, Cannon RO. Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet 1994; 343: 269-270.
31. [31] Adams MR, Kaplan JR, Manuck SB et al.. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomised monkeys: lack of an effect of added progesterone. Arteriosclerosis 1990; 10: 1051-1057.
32. [32] Chen SJ, Li H, Durand J, Oparil S, Chen YF. Estrogen reduces myointimal proliferation after balloon injury of rat carotid artery. Circulation 1996; 93 (3): 577-584.
33. [33] Lip GYH, Beevers M, Churchill D, Beevers DG. Hormone replacement therapy and blood pressure in hypertensive women. J Hum Hypertens 1994; 8: 491-494.
34. [34] Pines A, Fisman EZ, Schapira I et al. Exercise echocardiography in postmenopausal hormone users with mild hypertension. Am J Cardiol (December 1996).
35. [35] Hong MK, Romm PA, Reagan K, Green CE, Rackley CE. Effects of oestrogen replacement therapy on serum lipid values and angiographically defined coronary artery disease in postmenopausal women. Am J Cardiol 1992; 69: 176-178.
36. [36] Gruchow HW, Anderson AJ, Barboriak JJ, Sobocinski KA. Postmenopausal use of estrogen and occlusion of coronary arteries. Am Heart J 1988; 115: 954-963.
37. [37] McFarland KF, Boniface ME, Hornung CA, Earnhardt W, O'Neal-Humphries J. Risk factors and non-contraceptive estrogen use in women with and without coronary disease. Am Heart J 1989; 117: 1209-1214.
38. [38] Sullivan JM, Vander Zwaag R, Hughes JP et al. Estrogen replacement and coronary artery disease: effect on survival in postmenopausal women. Arch Intern Med 1990; 150: 2557-2562.
39. [39] Collins P, Rosano GMC, Sarrel PM et al. 17β-oestradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary artery disease. Circulation 1995; 92: 24-30.
40. [40] Eaker ED, Chesebro JH, Sacks FM et al. Cardiovascular disease in women. Circulation 1993; 88: 1999-2007.
41. [41] Rozenbaum H, Birkhauser MH. Consensus Propositions. In: Birkhauser MH, Rozenbaum H (ed.) Menopause - European Concensus Deveopment Conference, Montreux, Switzerland. Paris: Editions Eska, 1996, pp. 293-303.
42. [42] Kenemans P. Risk profile-based long-term hormone replacement therapy (Editorial). Eur Menopause J 1995; 2 (4): 3-4.